KR20030069796A - 졸피뎀 헤미타르트레이트 - Google Patents

졸피뎀 헤미타르트레이트 Download PDF

Info

Publication number
KR20030069796A
KR20030069796A KR1020027014220A KR20027014220A KR20030069796A KR 20030069796 A KR20030069796 A KR 20030069796A KR 1020027014220 A KR1020027014220 A KR 1020027014220A KR 20027014220 A KR20027014220 A KR 20027014220A KR 20030069796 A KR20030069796 A KR 20030069796A
Authority
KR
South Korea
Prior art keywords
zolpidem hemitartrate
zolpidem
hemitartrate
type
microns
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020027014220A
Other languages
English (en)
Korean (ko)
Inventor
주디스 아론히메
벤지온 돌리츠키
마르코 코르도바
다비드 레오노브
에르제베트 메스자로스-소스
스자볼레스 살리
엔첼 스크바르츠
크사바 스자보
슬로모 자부로브
Original Assignee
테바 파마슈티컬 인더스트리즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27394001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20030069796(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 테바 파마슈티컬 인더스트리즈 리미티드 filed Critical 테바 파마슈티컬 인더스트리즈 리미티드
Publication of KR20030069796A publication Critical patent/KR20030069796A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Other Liquid Machine Or Engine Such As Wave Power Use (AREA)
  • Suspension Of Electric Lines Or Cables (AREA)
  • Amplifiers (AREA)
  • Supply Devices, Intensifiers, Converters, And Telemotors (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020027014220A 2000-04-24 2001-04-24 졸피뎀 헤미타르트레이트 Ceased KR20030069796A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US19929800P 2000-04-24 2000-04-24
US60/199,298 2000-04-24
US20602500P 2000-05-22 2000-05-22
US60/206,025 2000-05-22
US22536400P 2000-08-14 2000-08-14
US60/225,364 2000-08-14

Publications (1)

Publication Number Publication Date
KR20030069796A true KR20030069796A (ko) 2003-08-27

Family

ID=27394001

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027014220A Ceased KR20030069796A (ko) 2000-04-24 2001-04-24 졸피뎀 헤미타르트레이트

Country Status (21)

Country Link
US (8) US20020077332A1 (https=)
EP (1) EP1292304B1 (https=)
JP (3) JP2003531173A (https=)
KR (1) KR20030069796A (https=)
AT (4) ATE338550T1 (https=)
AU (2) AU5721301A (https=)
CA (1) CA2406982A1 (https=)
CZ (1) CZ20023775A3 (https=)
DE (7) DE04010651T1 (https=)
DK (1) DK1292304T3 (https=)
ES (4) ES2239558T3 (https=)
HR (1) HRP20020909A2 (https=)
HU (1) HUP0300701A2 (https=)
IL (1) IL152411A0 (https=)
NZ (1) NZ522015A (https=)
PL (1) PL358548A1 (https=)
PT (3) PT1475093E (https=)
SE (1) SE5292304T3 (https=)
SK (1) SK16372002A3 (https=)
WO (1) WO2001080857A1 (https=)
YU (1) YU79402A (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001284322A1 (en) 2000-08-29 2002-03-13 Ranbaxy Laboratories Limited Synthesis of n,n-dimethyl-3-(4-methyl) benzoyl propionamide, a key intermediate of zolpidem
US6869970B2 (en) 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
ES2320758T3 (es) 2002-12-18 2009-05-28 Mallinckrodt Inc. Sintesis de heteroaril acetamidas.
WO2004087703A1 (en) * 2003-03-12 2004-10-14 Sun Pharmaceutical Industries Limited Process for the preparation of n,n,6-trimethyl-2-(4-methylphenyl)-imidazo[1,2-a]pyridine-3-acetamide
EP1660496A1 (en) * 2003-07-31 2006-05-31 Ranbaxy Laboratories Limited Process for the synthesis of zolpidem
EP1715853A4 (en) * 2004-02-17 2012-07-18 Transcept Pharmaceuticals Inc COMPOSITIONS FOR THE DISTRIBUTION OF HYPNOTICS IN THE FIELD OF MUNICHCHLEIMHÄUTE AND USE METHOD THEREOF
US20080262025A1 (en) * 2004-07-16 2008-10-23 Yatendra Kumar Processes for the Preparation of Zolpidem and its Hemitartrate
US20070225322A1 (en) * 2005-05-25 2007-09-27 Transoral Pharmaceuticals, Inc. Compositions and methods for treating middle-of-the night insomnia
US20070123562A1 (en) * 2005-05-25 2007-05-31 Transoral Pharmaceuticals, Inc. Compositions and methods for treating middle-of-the-night insomnia
US20070287740A1 (en) * 2005-05-25 2007-12-13 Transcept Pharmaceuticals, Inc. Compositions and methods of treating middle-of-the night insomnia
ES2336142T3 (es) * 2005-08-19 2010-04-08 Aventis Pharmaceuticals Inc. Combinacion de un agente hipnotico y un compuesto sustituido, con bis arilo y heteroarilo y aplicacion terapeutica del mismo.
KR20080034475A (ko) * 2005-08-19 2008-04-21 아벤티스 파마슈티칼스 인크. 수면제 및ｒ(＋)-알파-(2,3-디메톡시-페닐)-1-[2-(4-플루오로페닐)에틸]-4-피페리딘메탄올의 복합물 및 이의 치료학적 용도
AU2006297475A1 (en) * 2005-10-03 2007-04-12 Mallinckrodt Inc. Process for preparing zolpidem hemitartrate and tartrate polymorphs
EP1948134A2 (en) * 2005-10-17 2008-07-30 Mallinckrodt, Inc. Polymorph transformation of zolpidem in tablet matrix
US20070098788A1 (en) * 2005-10-28 2007-05-03 Gore Subhash P Non-benzodiazepine hypnotic compositions
PL2007752T3 (pl) 2006-03-31 2011-02-28 Janssen Pharmaceutica Nv Benzoimidazol-2-ilopirymidyny i pirazyny jako modulatory receptora histaminowego H4
US20080132535A1 (en) * 2006-11-30 2008-06-05 Transcept Pharmaceuticals, Inc. Stabilized Zolpidem Pharmaceutical Compositions
US20080145425A1 (en) * 2006-12-15 2008-06-19 Pliva Research & Development Limited Pharmaceutical composition of zolpidem
US20100029942A1 (en) * 2008-06-30 2010-02-04 Sergio Cesco-Cancian Process for the preparation of benzoimidazol-2-yl pyrimidine derivatives
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
CA3140959A1 (en) 2009-11-27 2011-06-03 Genzyme Corporation An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
WO2011115069A1 (ja) * 2010-03-19 2011-09-22 第一三共株式会社 結晶の網羅的探索
SMT202000084T1 (it) * 2013-03-06 2020-03-13 Janssen Pharmaceutica Nv Modulatori benzoimidazol-2-il pirimidinici del recettore h4 dell'istamina
CN116283958B (zh) * 2021-12-03 2026-02-24 山东新时代药业有限公司 唑吡坦共晶体及其制备方法
CN116283957A (zh) * 2021-12-03 2023-06-23 山东新时代药业有限公司 唑吡坦水合物及其制备方法
CN117907368A (zh) * 2024-01-27 2024-04-19 鲁南贝特制药有限公司 一种酒石酸唑吡坦药用晶型d中晶型a、e的定量测定方法
CN118750459B (zh) * 2024-07-22 2025-04-01 常州市武进中医医院 一种酒石酸唑吡坦片及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4151273A (en) * 1974-10-31 1979-04-24 The Regents Of The University Of California Increasing the absorption rate of insoluble drugs
FR2408345A1 (fr) * 1976-11-30 1979-06-08 Besins Jean Louis Nouvelle composition a action anti-conceptionnelle
US4302446A (en) * 1979-10-02 1981-11-24 Bristol-Myers Company Pharmaceutical compositions
IT1130924B (it) * 1980-03-06 1986-06-18 Secifarma Spa Procedimento per la preparazione di spironolattone micronizzato
DE3018940A1 (de) * 1980-05-17 1981-11-26 Hoechst Ag, 6000 Frankfurt Verwendung eines vinylchlorid-pfropf-copolymerisates in der plastisolverarbeitung
FR2492382A1 (fr) * 1980-10-22 1982-04-23 Synthelabo Derives d'imidazo (1,2-a) pyridine, leur preparation et leur application en therapeutique
FR2525601A1 (fr) * 1982-04-21 1983-10-28 Synthelabo Derives d'imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique
US4675323A (en) * 1985-08-06 1987-06-23 Synthelabo Imidazo(1,2-a)quinoline derivatives useful as anxiolytic agents
SE457326B (sv) * 1986-02-14 1988-12-19 Lejus Medical Ab Foerfarande foer framstaellning av en snabbt soenderfallande kaerna innehaallande bl a mikrokristallin cellulosa
FR2600650B1 (fr) * 1986-06-27 1988-09-09 Synthelabo Procede de preparation d'imidazopyridines et composes intermediaires
FR2606410B1 (fr) * 1986-11-07 1989-02-24 Synthelabo Imidazopyridines, leur preparation et leur application en therapeutique
ES2026666T3 (es) * 1987-03-27 1992-05-01 Synthelabo Procedimiento para preparar derivados de imidazopiridinas.
US5271944A (en) * 1991-04-05 1993-12-21 Biofor, Ltd. Pharmacologically enhanced formulations
IT1276522B1 (it) * 1995-04-07 1997-10-31 Elena Benincasa Uso dello zolpidem per il trattamento terapeudico di sindromi neuropsichiatriche associate a disfunsione e di circuiti neurali dei
ATE242241T1 (de) * 1999-03-25 2003-06-15 Synthon Bv Imidazopyridinderivate und verfahren zu ihrer herstellung
DE60020814T2 (de) * 1999-03-25 2006-05-04 Synthon B.V. Zolpidem salze
AU6474200A (en) * 1999-12-13 2001-06-18 Sumika Fine Chemicals Co., Ltd. Process for the preparation of a pyridinemethanol compound

Also Published As

Publication number Publication date
SK16372002A3 (sk) 2003-04-01
ATE308324T1 (de) 2005-11-15
DE60125429D1 (de) 2007-02-01
WO2001080857A1 (en) 2001-11-01
US20040214859A1 (en) 2004-10-28
US20040220212A1 (en) 2004-11-04
DE04010435T1 (de) 2005-09-01
ES2277301T3 (es) 2007-07-01
JP2006137778A (ja) 2006-06-01
DE60122944T2 (de) 2007-04-12
EP1292304A1 (en) 2003-03-19
ES2238941T3 (es) 2007-04-01
ES2239558T1 (es) 2005-10-01
US20020077332A1 (en) 2002-06-20
IL152411A0 (en) 2003-05-29
PL358548A1 (en) 2004-08-09
PT1475093E (pt) 2006-11-30
ATE348613T1 (de) 2007-01-15
JP2003531173A (ja) 2003-10-21
US20040220211A1 (en) 2004-11-04
EP1292304B1 (en) 2005-11-02
DE60122216T2 (de) 2007-08-30
PT1473036E (pt) 2006-10-31
PT1541146E (pt) 2007-01-31
EP1292304A4 (en) 2003-07-23
HRP20020909A2 (en) 2004-08-31
DE20122435U1 (de) 2005-10-06
DE04010651T1 (de) 2005-09-01
JP2006249105A (ja) 2006-09-21
DE60114617T2 (de) 2006-07-27
ATE335481T1 (de) 2006-09-15
US20040220213A1 (en) 2004-11-04
DE60122216D1 (de) 2006-09-21
DE60125429T2 (de) 2007-09-27
CA2406982A1 (en) 2001-11-01
ATE338550T1 (de) 2006-09-15
ES2238941T1 (es) 2005-09-16
CZ20023775A3 (cs) 2003-10-15
AU2001257213B2 (en) 2005-09-29
ES2248321T3 (es) 2006-03-16
WO2001080857A9 (en) 2002-06-27
DE60114617D1 (de) 2005-12-08
SE5292304T3 (https=) 2005-11-02
DK1292304T3 (da) 2005-12-19
US20070037843A1 (en) 2007-02-15
US20040220210A1 (en) 2004-11-04
YU79402A (sh) 2006-03-03
DE60122944D1 (de) 2006-10-19
NZ522015A (en) 2004-08-27
AU5721301A (en) 2001-11-07
US20040214858A1 (en) 2004-10-28
HUP0300701A2 (hu) 2003-07-28
ES2239558T3 (es) 2007-04-01

Similar Documents

Publication Publication Date Title
KR20030069796A (ko) 졸피뎀 헤미타르트레이트
AU2001257213A1 (en) Zolpidem hemitartrate
JP2021523918A (ja) Ｔｌｒ７／ｔｌｒ８阻害剤の結晶形態
JP2007514000A (ja) テガセロッド塩基及びその塩の多形現象形
HRP20100281A2 (hr) Kristalni oblici palonosetron hidroklorida
US7829711B2 (en) Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-C]pyridine-3-yl]-ethane-1,2-dione
EP1473036B1 (en) Zolpidem hemitartrate solvate
KR101423630B1 (ko) 비칼루타미드와 니코틴아미드의 공결정
JP2006511618A (ja) ガチフロキサシンの結晶形態および調製の方法
ZA200208454B (en) Zolpidem hemitartrate.
US20230373998A1 (en) Solid state forms of lorecivivint

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000